Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Accounts Payables · Q4 FY2024 · quarter ended Dec 2024

Accounts payables outflow grows to $0

Q4 FY2024 accounts payables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $0. Over 3 fiscal years it compounded at -67.1% a year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2024
$0— QoQ
Last fiscal yearDec 2025
-$1K-200.0% YoY
LTMDec 2024
$0— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-200.0%——
3-year CAGR-67.1%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1K) USD
Year-over-year change
-200.0%

Accounts Payables vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of -67.1% compares with a peer median of -15.7%.
MENS Competitors
Accounts Payables for MENS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$26.31M USD-138.8%-15.0%1.9%
DYNDyne Therapeutics, Inc.LTM Jun 2026$23.17M USD+98.6%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$15.45M USD+166.8%-33.0%2.3%
AAPGAscentage Pharma Group InternationalFY2025CN¥14.77M CNY-24.3%-15.7%2.6%
CNTACentessa Pharmaceuticals plcLTM Mar 2026$5.41M USD+322.6%-22.4%—
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$3.67M USD+225.9%-11.9%—
CELCCelcuity Inc.LTM Jun 2026$3.08M USD-161.9%——
TVTXTravere Therapeutics, Inc.LTM Sep 2026$2.72M USD+151.1%—0.4%
APGEApogee Therapeutics, Inc.LTM Jun 2026$2.6M USD-1820.5%-28.9%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$579K USD-86.5%+350.3%9.4%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024$0 USD—-67.1%—
Peer median (excluding MENS) —+37.1%-15.7%2.3%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Depreciation & Amortization122K123K127K120K100K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.24M2.94M1.12M(1.49M)20.74M
Accounts Receivables00000
Inventory00000
Accounts Payables21K(28K)(2K)1K(1K)
Other Working Capital1.22M2.97M1.12M(1.49M)20.74M
Other Non-Cash Items849K599K554K761K(19.21M)
Operating Cash Flow(1.98M)(2.97M)(2.6M)(3.62M)(3.04M)
Capital Expenditures(137K)(246K)000
Acquisitions (Net)00000
Purchases of Investments(1.83M)(292K)00(16.87M)
Sales of Investments664K1.93M95K016.87M
Other Investing Activities0000(13.51M)
Investing Cash Flow(1.31M)1.39M95K0(13.51M)
Debt Repayment(1.35M)3.61M2.47M2.2M(24K)
Common Stock Issued000017.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(35K)(276K)(445K)(213K)(114K)
Financing Cash Flow(1.38M)3.33M2.03M1.99M17.63M
Effect of Forex Changes67K(31K)(54K)(7K)(8K)
Net Change in Cash(4.61M)1.72M(532K)(1.64M)1.08M
Free Cash Flow(2.12M)(3.22M)(2.6M)(3.62M)(3.04M)

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.